Medicilon was selected as the "2023 Shanghai Professional Technical Service Platform"

On January 18, the Science and Technology Commission of Shanghai Municipality released the 2023 Shanghai Professional Technical Service Platform construction project list. There are only 29 platforms in Shanghai on the list.

Medicilon Preclinical Research (Shanghai) LLC, a subsidiary of Shanghai Medicilon Inc. (Medicilon), Nucleic Acid Drug R&D Service Platform was successfully selected! This is the Science and Technology Commission of Shanghai Municipality's high recognition of Medicilon's technological innovation and R&D capabilities, and is also a spur and incentive for Medicilon to continuously improve its service levels.

2023 Shanghai Professional Technical Service Platform.webp

The Shanghai professional technical service platform is an important part of Shanghai's scientific and technological innovation service system. It is a scientific research entity built on the basis of enterprises, scientific research institutes, universities or other institutions with scientific and technological innovation capabilities. It is oriented to the needs of scientific and technological innovation and economic and social development, and integrates various scientific and technological resources play a fundamental functional role in reducing the cost of scientific and technological innovation, promoting innovation-driven development, and creating a scientific and technological innovation ecosystem.

The Nucleic Acid Drug R&D Service Platform selected by Medicilon this time is an integrated and comprehensive platform integrating drug discovery, production and preclinical research. Based on rigorous scientific attitudes, open technology platforms, advanced instruments and equipment, as well as one-stop services for nucleic acid drug discovery, screening and preclinical research, it can shorten the research and development cycle, improve drug research and development efficiency, reduce costs, and promote new drugs to quickly enter the clinical stage.

Technological innovation is not achieved in a day, but comes from years of R&D investment and research. As a one-stop biopharmaceutical preclinical R&D service platform in China, Medicilon has always integrated technological innovation into development since its establishment nearly 20 years ago. Medicilon has accumulated rich R&D experience in the fields of ADC, small nucleic acids, PROTAC, and GLP-1. Medicilon has served more than 50 ADC clients and currently has more than 30 projects under development, has served more than 40 small nucleic acid clients and has more than 20 projects under development, has served more than 30 PROTAC-related customers and nearly 20 projects are under development, and has also helped 8 GLP-1 related drugs obtain clinical approval.

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Shanghai Medicilon Inc.

搜索此博客